Literature DB >> 8784094

Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction.

B D Anawalt1, R A Bebb, A M Matsumoto, N P Groome, P J Illingworth, A S McNeilly, W J Bremner.   

Abstract

We used a recently developed ELISA format to test the hypothesis that inhibin B is the physiologically active form of inhibin in men. We measured and compared inhibin A, inhibin B, and pro-alpha-C-related immunoreactive peptides (pro-alpha-C-RI) in normal men before and after perturbations of their gonadotropin levels and baseline values in normal men and men with various disturbances of the hypothalamic-pituitary-testicular axis including men with idiopathic hypogonadotropic hypogonadism, infertile men with elevated FSH, men with Klinefelter's syndrome, and orchidectomized men. Mean serum inhibin concentrations were significantly higher in normal men than untreated men with idiopathic hypogonadotropic hypogonadism, infertile men with elevated FSH, untreated men with Klinefelter's syndrome, and orchidectomized men (187 +/- 28 vs 45 +/- 11, 37 +/- 6, 11 +/- 3, and < or = 10 pg/mL, respectively; P < 0.05). Inhibin B levels were below the limit of detection in all of the orchidectomized men. Pro-alpha-C-RI levels were detectable in all men studied including the orchidectomized men, and no significant differences in the pro-alpha-C-RI levels were noted between the normal men and men with various testicular diseases were noted except that orchidectomized men had significantly lower pro-alpha-C-RI levels than all other groups (P < 0.05). Inhibin A was undetectable in all men tested in this study. Six normal men who were administered exogenous levonorgestrel and testosterone had significantly lower serum gonadotropin, inhibin B, and pro-alpha-C-RI levels during the treatment period than the control and recovery periods (P < 0.05). Ten normal men who were administered human recombinant FSH had significantly higher peak serum FSH (21.85 +/- 3.23 IU/L vs. 3.01 +/- 0.51 IU/L), inhibin B (311 +/- 88 pg/mL vs. 151 +/- 23 pg/mL) and pro-alpha-C-RI (646 +/- 69 vs. 402 +/- 38 pg/mL) levels during the treatment period than the baseline values (P < 0.05). We conclude that inhibin B is a unique testicular product that is not detectable in the sera of orchidectomized men, is responsive to FSH stimulation, and has a reciprocal relationship with serum FSH levels in men with various forms of testicular disease. Therefore, inhibin B is likely to be the physiologically important form of inhibin in men.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784094     DOI: 10.1210/jcem.81.9.8784094

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

1.  Sox3 is required for gonadal function, but not sex determination, in males and females.

Authors:  Jeffrey Weiss; Joshua J Meeks; Lisa Hurley; Gerald Raverot; Andrea Frassetto; J Larry Jameson
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

2.  Pituitary-gonadal axis in male undermasculinisation.

Authors:  K L Ng; S F Ahmed; I A Hughes
Journal:  Arch Dis Child       Date:  2000-01       Impact factor: 3.791

3.  Pyrethroid insecticide metabolites are associated with serum hormone levels in adult men.

Authors:  John D Meeker; Dana B Barr; Russ Hauser
Journal:  Reprod Toxicol       Date:  2009-01-24       Impact factor: 3.143

4.  Inhibin B levels in hypothyroid males.

Authors:  Peter Donnelly; Kris Tan; Denis Winch
Journal:  Thyroid       Date:  2013-09-20       Impact factor: 6.568

Review 5.  Consensus statement on diagnosis and clinical management of Klinefelter syndrome.

Authors:  A F Radicioni; A Ferlin; G Balercia; D Pasquali; L Vignozzi; M Maggi; C Foresta; A Lenzi
Journal:  J Endocrinol Invest       Date:  2010-12       Impact factor: 4.256

6.  Tissue-specific expression of inhibin/activin subunit and follistatin mRNAs in mid- to late-gestational age human fetal testis and epididymis.

Authors:  V J Roberts
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

Review 7.  Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism.

Authors:  A Lenzi; G Balercia; A Bellastella; A Colao; A Fabbri; C Foresta; M Galdiero; L Gandini; C Krausz; G Lombardi; F Lombardo; M Maggi; A Radicioni; R Selice; A A Sinisi; G Forti
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

8.  The Story of SPATA2 (Spermatogenesis-Associated Protein 2): From Sertoli Cells to Pancreatic Beta-Cells.

Authors:  Claudio Maran; Evelyne Tassone; Valentina Masola; Maurizio Onisto
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

9.  Weaning and the developmental changes in follicle-stimulating hormone, pituitary adenylate cyclase-activating polypeptide, and inhibin B in the male rat.

Authors:  Joseph P Moore; Stephen J Winters
Journal:  Biol Reprod       Date:  2007-12-26       Impact factor: 4.285

10.  Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function.

Authors:  Jaap J M Teunissen; Eric P Krenning; Frank H de Jong; Yolanda B de Rijke; Richard A Feelders; Maarten O van Aken; Wouter W de Herder; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.